Skip to main content

Advertisement

SpringerLink
Log in

Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208

  • Published:
Journal of Cancer Survivorship Aims and scope Submit manuscript

Abstract

Purpose

We describe 7 years of follow-up for the energy/vitality outcome in early-stage Hodgkin’s disease patients treated on a randomized clinical trial that compared subtotal lymphoid irradiation (STLI) with combined modality treatment (CMT) (SWOG 9133). Survivorship research questions involved the extent to which symptoms/side effects endured over a follow-up period of 7 years for this early-stage patient group.

Methods

Two hundred thirty-nine patients participated in the quality of life (QOL) companion study (SWOG 9208) and completed the SF-36 vitality scale, SF-36 health perception item, Cancer Rehabilitation Evaluation System-Short Form (CARES-SF), and symptom distress scale. This paper reports vitality outcome results obtained from randomization, 6 months, and annually for 7 years. To assess changes in vitality over time, we used linear mixed models with patient as a random effect.

Results

Patients receiving CMT had lower observed vitality at 6 months than did the STLI patients (p < .0001). However, beginning at year 1, vitality results did not differ significantly by treatment over the 5-year (p = .13) and 7-year (p = .16) follow-up periods. Vitality only slightly improved over baseline in either group after treatment. The results were similar after accounting for patterns of recurrence and missing data.

Conclusions

This study demonstrated that patients with early-stage Hodgkin’s disease experience a short-term (at 6 months) decrease in vitality with treatment, which is more severe with CMT, but that after the first year, vitality scores were similar between the two treatment groups. Enduring fatigue results for patients receiving these therapies were not observed.

Implications for cancer survivors

These data provide comprehensive 7-year follow-up vitality information, an important symptom for early-stage lymphoma survivors.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Bower JE, Ganz PA, Desmond KA, Rowland JH, Meyerowitz BE, Belin TR. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol. 2000;18(4):743–53.

    CAS  PubMed  Google Scholar 

  2. Bower JE, Bak K, Berger A, Breitbart W, Escalante CP, Ganz PA, et al. Screening, assessment, and management of fatigue in adult survivors of cancer: an American Society of Clinical oncology clinical practice guideline adaptation. J Clin Oncol. 2014;32(17):1840–50. doi:10.1200/JCO.2013.53.4495.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Roper K, McDermott K, Cooley ME, Daley K, Fawcett J. Health-related quality of life in adults with Hodgkin’s disease: the state of the science. Cancer Nurs. 2009;32(6):E1–17. doi:10.1097/NCC.0b013e3181aa4a33.

    Article  PubMed  Google Scholar 

  4. Oerlemans S, Mols F, Nijziel MR, Lybeert M, van de Poll-Franse LV. The impact of treatment, socio-demographic and clinical characteristics on health-related quality of life among Hodgkin’s and non-Hodgkin’s lymphoma survivors: a systematic review. Ann Hematol. 2011;90(9):993–1004. doi:10.1007/s00277-011-1274-4.

    Article  PubMed  PubMed Central  Google Scholar 

  5. Network NCC. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Survivorship. Fort Washington: NCCN; 2013. http://www.nccn.org/about/news/newsinfo.aspx?NewsID=333. Accessed 14 March 2013.

    Google Scholar 

  6. Stasi R, Abriani L, Beccaglia P, Terzoli E, Amadori S. Cancer-related fatigue: evolving concepts in evaluation and treatment. Cancer. 2003;98(9):1786–801. doi:10.1002/cncr.11742.

    Article  PubMed  Google Scholar 

  7. Ganz PA, Moinpour CM, Pauler DK, Kornblith AB, Gaynor ER, Balcerzak SP, et al. Health status and quality of life in patients with early-stage Hodgkin’s disease treated on Southwest Oncology Group Study 9133. J Clin Oncol. 2003;21(18):3512–9. doi:10.1200/JCO.2003.01.044.

    Article  PubMed  Google Scholar 

  8. Authors. Author Corrections. J Clin Oncol. 2013;31(17):2231–2.

  9. Press OW, LeBlanc M, Lichter AS, Grogan TM, Unger JM, Wasserman TH, et al. Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin’s disease. J Clin Oncol. 2001;19(22):4238–44.

    CAS  PubMed  Google Scholar 

  10. Ware JE, Snow KK, Kosinski M, Gandek B. New England Medical Center Hospital. Health Institute. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.

    Google Scholar 

  11. Daniëls LA, Oerlemans S, Krol AD, van de Poll-Franse LV, Creutzberg CL. Persisting fatigue in Hodgkin lymphoma survivors: a systematic review. Ann Hematol. 2013;92(8):1023–32. doi:10.1007/s00277-013-1793-2.

    Article  PubMed  Google Scholar 

  12. Daniëls LA, Oerlemans S, Krol AD, Creutzberg CL, van de Poll-Franse LV. Chronic fatigue in Hodgkin lymphoma survivors and associations with anxiety, depression and comorbidity. Br J Cancer. 2014;110(4):868–74. doi:10.1038/bjc.2013.779.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Heutte N, Flechtner HH, Mounier N, Mellink WA, Meerwaldt JH, Eghbali H, et al. Quality of life after successful treatment of early-stage Hodgkin’s lymphoma: 10-year follow-up of the EORTC-GELA H8 randomised controlled trial. Lancet Oncol. 2009;10(12):1160–70. doi:10.1016/S1470-2045(09)70258-X.

    Article  PubMed  Google Scholar 

  14. Evens AM, Wagner LI. Curing Hodgkin’s lymphoma: quantity and quality. Lancet Oncol. 2009;10(12):1134–5. doi:10.1016/S1470-2045(09)70339-0.

    Article  PubMed  Google Scholar 

  15. Ware Jr JE, The SCD, MOS. 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30(6):473–83.

    Article  PubMed  Google Scholar 

  16. McHorney C, Ware Jr JE, The RA, MOS. 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31(3):247–63.

    Article  CAS  PubMed  Google Scholar 

  17. McHorney CA, Ware Jr JE, Lu JF, The SCD, MOS. 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care. 1994;32(1):40–66.

    Article  CAS  PubMed  Google Scholar 

  18. Deng N, Guyer R, Ware Jr JE. Energy, fatigue, or both? A bifactor modeling approach to the conceptualization and measurement of vitality. Qual Life Res. 2015;24(1):81–93. doi:10.1007/s11136-014-0839-9.

    Article  PubMed  Google Scholar 

  19. Reise SP, Morizot J, Hays RD. The role of the bifactor model in resolving dimensionality issues in health outcomes measures. Qual Life Res. 2007;16(Supplement 1):19–31. doi:10.1007/s11136-007-9183-7.

    Article  PubMed  Google Scholar 

  20. Schag CAC, Ganz PA, Heinrich RL. Cancer Rehabilitation Evaluation System—Short Form (CARES-SF): a cancer specific rehabilitation and quality of life instrument. Cancer. 1991;68:1406–13.

    Article  CAS  PubMed  Google Scholar 

  21. McCorkle R, Benoliel JQ. Symptom distress, current concerns, and mood disturbance after diagnosis of life threatening disease. Soc Sci Med. 1983;17:431–8.

    Article  CAS  PubMed  Google Scholar 

  22. McCorkle R, Cooley ME, Shea JA. A user’s manual for the symptom distress scale. Philadelphia: University of Pennsylvania School of Nursing; 1998.

    Google Scholar 

  23. Ware Jr JE. Monitoring and evaluating health services. Med Care. 1985;23(5):705–9.

    Article  PubMed  Google Scholar 

  24. Zubrod CG, Schneiderman M, Frei E, Brindley C, Gold GL, Shnider B, et al. Appraisal of methods for the study of chemotherapy in man: comparative therapeutic trial of nitrogen mustard and thiophosphoramide. J Chronic Diseases. 1960;11:7–33.

    Article  Google Scholar 

  25. Breslow NE, Clayton DG. Approximate Inference in generalized linear mixed models. J Am Stat Assoc. 1993;88(421):9–25. doi:10.2307/2290687.

    Google Scholar 

  26. Little RJA, Wang YX. Pattern-mixture models for multivariate incomplete data with covariates. Biometrics. 1996;52(1):98–111. doi:10.2307/2533148.

    Article  CAS  PubMed  Google Scholar 

  27. SAS Institute Inc. Base SAS® 9.4 Procedures Guide: Statistical Procedures. 2nd edition. Cary: NC2013

  28. Eich HT, Diehl V, Görgen H, Pabst T, Markova J, Debus J, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin’s lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol. 2010;28(27):4199–206. doi:10.1200/JCO.201029.8018.

    Article  PubMed  Google Scholar 

  29. Engert A, Plütschow A, Eich HT, Lohri A, Dörken B, Borchmann P, et al. Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. New Engl J Med. 2010;363(7):640–52.

    Article  CAS  PubMed  Google Scholar 

  30. Raemaekers JMM, André MPE, Federico M, Girinsky T, Oumedaly R, Brusamolino E, et al. Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA?FIL H10 trial. J Clin Oncol. 2014;32(12):1188–94. doi:10.1200/JCO.2013.51.9298.

    Article  PubMed  Google Scholar 

  31. Radford J, Illidge T, Counsell N, Hancock B, Pettengell R, Johynson P, et al. Results of a trial of PET_directed therapy for early-stage Hodgkin’s lymphoma. N Engl J Med. 2015;372(17):1598–607. doi:10.1056/NEJMoa1408648.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We thank the patients and research staff at SWOG and CALGB institutions for providing the QOL outcome data that allowed us to monitor for effects of treatment on vitality over a 7-year period.

Author information

Authors and Affiliations

  1. Public Health Sciences Division, SWOG Statistical Center, Fred Hutchinson Cancer Research Center, M3-C102/P.O. Box 19024, 1100 Fairview Avenue North, Seattle, WA, 98109-1024, USA

    Carol M. Moinpour & Joseph M. Unger

  2. School of Public Health, University of Washington, Seattle, WA, USA

    Carol M. Moinpour & Joseph M. Unger

  3. UCLA Fielding School of Public Health, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, CA, USA

    Patricia A. Ganz

  4. 140 8th Ave, Apt4-O, Brooklyn, NY, USA

    Alice B. Kornblith

  5. Stritch School of Medicine, Cardinal Bernardin Cancer Center, Loyola University, Maywood, IL, USA

    Ellen R. Gaynor

  6. Division of Nephrology, Nephrology Clinical Trials Unit, The Ohio State University, Columbus, OH, USA

    Mindy Ann Bowers

  7. Mark H. Zangmeister Center, Columbus CCOP, Columbus, OH, USA

    Gretchen S. Gatti

  8. Department of Internal Medicine, Division of Hematology/Oncology, University of Michigan Comprehensive Cancer Center, Ann Arbor, MI, USA

    Mark S. Kaminski

  9. Division of Hematology/Oncology, The Kirklin Clinic-Birmingham, Birmingham, AL, USA

    Harry Paul Erba

  10. Educational Psychology Dept. (PhD program), College of Education, University of Washington, Seattle, WA, USA

    Ting Wang

  11. Public Health Sciences Division, Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

    Jihye Yoon

  12. Fred Hutchinson Cancer Research Center and University of Washington, Seattle, WA, USA

    Oliver W. Press

  13. Fox Chase Cancer Center, Temple University School of Medicine, Philadelphia, PA, USA

    Richard I. Fisher

Authors
  1. Carol M. Moinpour
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Joseph M. Unger
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Patricia A. Ganz
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Alice B. Kornblith
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ellen R. Gaynor
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Mindy Ann Bowers
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Gretchen S. Gatti
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Mark S. Kaminski
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Harry Paul Erba
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ting Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Jihye Yoon
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Oliver W. Press
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Richard I. Fisher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Carol M. Moinpour.

Ethics declarations

Funding

This investigation was supported by NIH/NCI NCTN grants CA180888, CA180819, CA180821, CA180801, CA180818, CA180834, CA180835, and CA180828; NIH/NCI NCORP grants CA189974, CA189954, CA189953, CA189952, CA189853, CA189854, CA189830, CA189872, CA189804, CA189957, and CA189808; and legacy grants NIH/NCI grants CA32102, CA38926,CA37429, CA46282, CA46368, CA22433, CA58415, CA13612, CA76447, CA46113, CA76132, CA58723, CA12644, CA 35128, CA12213, CA52654, CA58658, CA35996, CA76429, CA16385, CA74647, CA76462, CA37981, CA58348, CA35119, and CA35262. Clinical trials registration identification number NCT00002563.

Conflict of interest

The authors declare that they have no conflicts of interest.

Ethical approval

All procedures performed in the studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in this study.

Electronic supplementary material

Below is the link to the electronic supplementary material.

ESM 1

(PDF 49 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Moinpour, C.M., Unger, J.M., Ganz, P.A. et al. Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin’s disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11, 32–40 (2017). https://doi.org/10.1007/s11764-016-0559-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11764-016-0559-y

Keywords

Search

Navigation